Search Filters:

The items contained in the list are being used to filter the search results. Click them to remove them from the search filter.
Displaying 201 - 220 of 1097
PIPS Search Results
PIP Number Active Substance Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Compliance outcome Date Published Sort ascending
MHRA-101301-PIP01-23
  • Fusion protein consisting of relaxin and Fc domain of IgG1
  • Treatment of pulmonary hypertension due to left heart disease.
  • Not available at present
  • Cardiovascular Diseases
W: decision granting a waiver in all age groups for the listed condition(s). No 03/10/2024
MHRA-101315-PIP01-23
  • NIVOLUMAB
  • relatlimab
  • Treatment of all conditions in the category of malignant neoplasms (except nervous system neoplasms, haematopoietic and lymphoid tissue neoplasms and melanoma)
  • Opdualag
  • Opdualag
  • Opdualag
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No 03/10/2024
MHRA-101313-PIP01-23
  • maplirpacept
  • Treatment of multiple myeloma.
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No 03/10/2024
MHRA-101247-PIP01-23
  • empasiprubart
  • Treatment of multifocal motor neuropathy
  • empasiprubart
  • Neurology
W: decision granting a waiver in all age groups for the listed condition(s). No 03/10/2024
MHRA-101236-PIP01-23
  • Rilzabrutinib
  • Treatment of autoimmune haemolytic anaemia.
  • Haematology-Hemostaseology
W: decision granting a waiver in all age groups for the listed condition(s). No 03/10/2024
MHRA-101242-PIP01-23-M01 (update)
  • LUMASIRAN SODIUM
  • Treatment of hyperoxaluria.
  • Oxlumo
  • Uro-Nephrology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 03/10/2024
MHRA-101159-PIP01-23
  • MK 2870- Humanised IgG1 monoclonal antibody against TROP2, conjugated to a topoisomerase I inhibitor belotecan-derivative
  • Treatment of lung cancer
  • Treatment of cervical cancer
  • Treatment of ovarian cancer
  • Treatment of endometrial cancer
  • Treatment of gastric cancer
  • Treatment of breast cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No 03/10/2024
MHRA-101175-PIP01-23
  • baxdrostat
  • Treatment of hypertension
  • Not available at present
  • Cardiovascular Diseases
W: decision granting a waiver in all age groups for the listed condition(s). No 03/10/2024
MHRA-101151-PIP01-23-M01 (update)
  • OBETICHOLIC ACID
  • Treatment of primary biliary cirrhosis
  • Treatment of biliary atresia
  • Ocaliva
  • Ocaliva
  • Ocaliva
  • Ocaliva
  • Ocaliva
  • Ocaliva
  • Ocaliva
  • Ocaliva
  • Ocaliva
  • Ocaliva
  • Ocaliva
  • Ocaliva
  • Ocaliva
  • Ocaliva
  • Ocaliva
  • Ocaliva
  • Ocaliva
  • Gastroenterology-Hepatology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 03/10/2024
MHRA-100146-PIP01-21
  • tezepelumab
  • Treatment of eosinophilic esophagitis
  • Gastroenterology-Hepatology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 03/10/2024
MHRA-101111-PIP01-23
  • Cendakimab (BMS-986355)
  • Treatment of Eosinophilic Esophagitis (EoE)
  • Immunology -Rheumatology-Transplantation
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 03/10/2024
MHRA-101349-PIP01-24
  • SECUKINUMAB
  • Treatment of rotator cuff tendinopathy
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Immunology -Rheumatology-Transplantation
W: decision granting a waiver in all age groups for the listed condition(s). No 15/08/2024
MHRA-101246-PIP01-23-M01 (update)
  • MEROPENEM
  • VABORBACTAM
  • Treatment of Gram-negative bacterial infections
  • Vaborem
  • Vaborem
  • Vabomere
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No 15/08/2024
MHRA-101000-PIP01-23-M02 (update)
  • Rilzabrutinib
  • Treatment of immune thrombocytopenia.
  • Immunology -Rheumatology-Transplantation
PM: decision on the application for modification of an agreed paediatric investigation plan. No 15/08/2024
MHRA-100678-PIP01-22-M01 (update)
  • vamikibart
  • Treatment of uveitic macular oedema
  • Ophthamology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 15/08/2024
MHRA-101282-PIP01-23
  • eftilagimod alfa
  • Treatment of non-small cell lung cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No 15/08/2024
MHRA-101094-PIP01-23-M01 (update)
  • Givinostat
  • Treatment of Duchenne muscular dystrophy
  • Neurology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 15/08/2024
MHRA-100743-PIP01-22-M02 (update)
  • efgartigimod alfa
  • Treatment of myasthenia gravis
  • Vyvgart
  • Vyvgart
  • Vyvgart
  • Vyvgart Hytrulo
  • Vyvgart
  • Vyvdura
  • Vyvgart
  • Vyvgart
  • Vyvgart
  • Vyvgart
  • Vyvgart
  • Vyvgart
  • Neurology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 15/08/2024
MHRA-100312-PIP01-21-M02 (update)
  • RITLECITINIB TOSYLATE
  • Treatment of alopecia areata
  • Litfulo
  • Litfulo
  • Litfulo
  • Litfulo
  • Litfulo
  • Dermatology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 15/08/2024
MHRA-100216-PIP01-21-M03 (update)
  • TRALOKINUMAB
  • treatment of atopic dermatitis
  • Adtralza
  • Adtralza
  • Adtralza
  • Adbry
  • Adtralza
  • Adtralza
  • Adtralza
  • Adtralza
  • Adtralza
  • Adtralza
  • Dermatology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 15/08/2024